COMPLETE DRUG INFORMATION, A KEY FOR SAFE THERAPY- A COMPARATIVE EVALUATION OF DRUG BROCHURES USED FOR DISSEMINATING DRUG INFORMATION BY PHARMACEUTICAL COMPANIES IN PAKISTAN AND MALAYSIA
Author(s)
Masood I1;Ibrahim MI2;Hassali MA3;Ahmad M*1;Shafie AA3;Saleem F4, Masood MI5 1The Islamia University of Bahawalpur, Bahawalpur, Pakistan, 2College of Pharmacy, Qatar University, doha, Qatar, 3Universiti Sains Malaysia, Penang, Malaysia, 4UNIVERSITI SAINS MALAYSIA, PENANG, Malaysia, 5The University of Veterinary and Animal Sciences, Lahore, Pakistan
OBJECTIVES: To evaluate the consistency of information given in drug brochures by pharmaceutical companies METHODS: Total of 500 drug brochures were collected from the doctors’ clinics in Pakistan and 473 brochures were collected from the general practitioners’ clinics in Malaysia. After comprehensive scrutiny, a total of 498 brochures were included and evaluated for the study. An evaluation form was developed based on the criteria given by WHO, FIPMA, DCOMOH(Pakistan) and PhAMA. The data was analyzed using SPSS. To summarize the data, descriptive statistics (frequencies, percentages,) were calculated and Chi-square test and Fisher’s exact test were applied as inferential statistics. A Pvalue of less than 0.05 was considered as statistical significance for all the tests. RESULTS: The Cronbach’s coefficient Alpha value was 0.729 (n=50). The study found that the dosage form was presented significantly (P=0.009) less in national companies’ (NCs) brochures as compared to MNCs. MNCs were found significantly adherent to the standard criteria for brochures as compared to NCs for presenting drug interactions (P<0.001), precautions (P<0.001) and expected ADRs (P<0.001). National companies were found significantly (P<0.001) adherent to the standard criteria in terms of presenting contraindications and warnings. MNCs were significantly better (P=0.009) in terms of including contact information in the brochures. A significantly higher number of Malaysian brochures providing information about drug interactions (P<0.001), precautions (P<.001), expected ADRs (P<0.001) and contraindications (P<0.001). On average 3 (median, IQR=5) references were used in the brochures out of which on average 2 (median, IQR=6) references were understandable. The references having enough information to access particular study were considered understandable. CONCLUSIONS: The drug information given in the brochures, discrepancies are observed mainly in drug safety related information like side effects, possible ADRs, precautions etc. The references cited in the brochures were also found to be inappropriate and incomplete.
Conference/Value in Health Info
2013-05, ISPOR 2013, New Orleans, LA, USA
Value in Health, Vol. 16, No. 3 (May 2013)
Code
PHP82
Topic
Real World Data & Information Systems
Topic Subcategory
Health & Insurance Records Systems
Disease
Multiple Diseases